explore -WSS

explore

author：entertainment 2025-10-01 15:43:00 - browse：731

Susan Galbraith of AstraZeneca gestures while speaking – pharma coverage from STAT — Susan Galbraith, AstraZeneca’s head of cancer research and development, speaks at a STAT event in 2023. Marie Miller for STAT

CHICAGO — AstraZeneca’s head of cancer research and development, Susan Galbraith, is British, and prone to a particularly British style of understatement. She doesn’t boast loudly. But she did come to this year’s annual meeting of the American Society of Clinical Oncology wearing a small lapel pin with the numeral 6 and the “AZ” corporate logo.

That pin represents the number of years in a row that the London-based drug giant has had a presentation in the ASCO plenary, the conference’s biggest showcase for new data. This year, the company has two.

Scientific credibility is great, of course. But AstraZeneca’s shareholders want something else: return on investment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

leisure time

WSS

Pfizer is about to make a big push in cancer. Will investors listen?

‘Oppenheimer’ and the risks of AI in health care

‘Oppenheimer’ and the risks of AI in health care

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Redefining sustainability for the pharmaceutical industry

Medicare Advantage isn’t working — for anyone

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Virginia high school admissions case could be legal follow

Mega Millions pot grows to $1.25 billion after no winner

Virginia high school admissions case could be legal follow

Childhood vaccination ad campaign launches in the U.K.

In age of alternative facts, a scholarly course on calling out crap

Breakthrough Alzheimer’s drugs are inaccessible in rural states

Alkermes shareholders re

New safety details link Apellis eye drug to rare cases of blindness

The cancer drug shortage isn’t new — and neither are the solutions

Medicare isn't yet testing food as medicine

explore

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

Virtual repurposing can help discover new uses for existing drugs

Children’s Hospital revives plan for pedestrian bridge

New safety details link Apellis eye drug to rare cases of blindness

CDC advisory group OKs chikungunya vaccine

Laying a path for careers in science

leisure time

focus

focus

leisure time